Gastrointestinal Neuroendocrine Tumors Market

• The total Gastrointestinal Neuroendocrine Tumors market size in the 7MM is expected to grow with a significant CAGR during the forecast period due to rising incidence, earlier diagnosis, and expanding treatment options.
• In recent years, radioactive isotopes have garnered significant attention from the pharmaceutical industry due to their growing clinical use in both diagnosing and treating various cancers.
• The management of Gastrointestinal Neuroendocrine Tumors is increasingly shifting towards endoscopic approaches, reducing the need for surgery. Many Gastrointestinal Neuroendocrine Tumors are detected during routine endoscopies or colonoscopies and are simultaneously removed if they are small enough.
• LUTATHERA sales grew mainly in the US, Europe and Japan due to increased demand and earlier line adoption particularly in the US and Japan.
• Long-acting octreotide formulations, such as Novartis' SANDOSTATIN LAR, have been widely used as a first-line treatment for Gastrointestinal Neuroendocrine Tumors. Despite its strong market uptake post-approval, SANDOSTATIN LAR's sales are now declining due to generic competition in the European market. However, an AB-rated generic version has been launched in the US by TEVA Pharmaceuticals.
• In May 2025, Advanced Accelerator Applications, a Novartis Company, has taken the decision to withdraw the Type II variation application to extend the indication of LUTATHERA, for the treatment of newly diagnosed, unresectable or metastatic, well-differentiated (Grade (G2) and G3), somatostatin receptor-positive GEP-NETs in adults.
• Since only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha emitters. Alpha particles have a higher linear energy transfer (LET) than beta particles, allowing for greater biological damage and the potential to overcome radio- and chemoresistance. Companies like Bristol Myers Squibb/RayzeBio, Perspective Therapeutics, and others are actively working in this area.
• The Gastrointestinal Neuroendocrine Tumors indication has a strong pipeline, with many companies actively developing Gastrointestinal Neuroendocrine Tumors therapies. Key players include ITM Solucin GmbH, Camurus, BMS, RayzeBio, Crinetics Pharmaceuticals, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Elicera Therapeutics, and Shanghai EpimAb Biotherapeutics among others.

DelveInsight’s “Gastrointestinal Neuroendocrine Tumors (Gastrointestinal Neuroendocrine Tumors) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of Gastrointestinal Neuroendocrine Tumors, historical and forecasted epidemiology as well as Gastrointestinal Neuroendocrine Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Gastrointestinal Neuroendocrine Tumors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Gastrointestinal Neuroendocrine Tumors market size from 2020 to 2034. The report also covers current Gastrointestinal Neuroendocrine Tumors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Key Factors Driving the Growth of the Gastrointestinal Neuroendocrine Tumors Market 

Rising GI-NET Incident Cases 

The total number of incident cases of GI-NETs in the US was nearly 15,500 cases in 2024 and is projected to increase by 2034 due to improved diagnostic capabilities and enhanced imaging and endoscopic techniques, which enable earlier and more accurate detection of these tumors.

Advancements in Diagnostic Technologies

Innovations in diagnostic tools, including advanced imaging techniques and biomarker identification, have improved the accuracy of GI-NET detection. These advancements enable clinicians to identify tumors at earlier stages, resulting in improved patient outcomes and contributing to market growth.

Launch of Emerging GI-NET Therapies

The expected launch of GI-NET therapies, such as ITM-11 (n.c.a. 177Lu-edotreotide) (ITM Solucin GmbH), CAM2029 (Camurus), RYZ101 (Actinium-225 DOTATATE) (Bristol Myers Squibb/RayzeBio), and others, is expected to change the market dynamics in the coming years.

Gastrointestinal Neuroendocrine Tumors Understanding and Treatment Algorithm

Gastrointestinal Neuroendocrine Tumors is a specific type of NETs. Like all cancers, Gastrointestinal Neuroendocrine Tumors are named after the place they start growing. For example, a NETs that starts in the GI is called a Gastrointestinal Neuroendocrine Tumors. This is the primary cancer. If the cancer spreads to another part of the body, it’s called secondary cancer. Gastrointestinal Neuroendocrine Tumors are NETs tumors that form in the GI tract, mainly in the rectum, small intestine, or appendix. Symptoms are the basic which includes pain in the GI area, a growing lump under the skin, feeling unusually tired, and losing weight. The staging for each of these is slightly different, but they all have stages 1 through 4, with higher stages representing more advanced cancer that may be more difficult to treat. Some may have sub stages that provide even more description of where the cancer cells are found. They can be indolent or aggressive. The WHO has given a separate classification of grouping Gastrointestinal Neuroendocrine Tumors. The exact causes of Gastrointestinal Neuroendocrine Tumors are unknown, but there are numerous associated risk factors, including pituitary adenoma, Von Hippel-Lindau (VHL), pheochromocytomas, etc. Gastrointestinal Neuroendocrine Tumors grow at different rates, but they often grow very slowly. Some might not grow at all for months or years. So, it might not need treatment straight away.

Gastrointestinal Neuroendocrine Tumors Diagnosis

Gastrointestinal Neuroendocrine Tumors are often diagnosed late—typically 5 to 7 years after symptom onset—due to their nonspecific or asymptomatic presentation. By diagnosis, metastases are present in about 30% of NET cases and up to 70% in midgut NETs, while neuroendocrine carcinomas (NECs) frequently present at advanced stages due to their aggressive nature. Diagnosis involves a combination of biochemical testing, imaging, genetic assays, and endoscopic evaluations. Chromogranin A (CgA) and 24-hour urine 5-HIAA are commonly used biochemical markers, although both have limitations. Emerging tools like the NETest offer higher sensitivity and specificity through gene expression profiling. Imaging, including CT, MRI, and somatostatin receptor-based PET scans, is essential for lesion detection and staging, while FDG-PET is reserved for high-grade NECs. Endoscopic techniques, including capsule endoscopy and enterography, help localize small bowel lesions, though capsule use is limited due to obstruction risks. Additionally, echocardiography is recommended for detecting carcinoid heart disease in patients with serotonin-producing tumors before surgery.

Further details related to diagnosis are provided in the report…

Gastrointestinal Neuroendocrine Tumors Treatment

Treatment for Gastrointestinal Neuroendocrine Tumors depends on several things, including where the cancer is, its size, and whether it has spread. Surgery has been traditionally considered to be the main treatment of Gastrointestinal Neuroendocrine Tumors; however, in recent decades there has been a considerable evolution of several nonsurgical treatments that have expanded the therapeutic options of these neoplasms. In patients with advanced disease, tumor debulking techniques such as partial gastrectomy, selective internal radiotherapy (SIRT), radiofrequency ablation (RFA), small intestine resection, abdominoperineal resection and lower anterior resection may significantly decrease the tumor burden or lead to symptomatic improvement of hormone excess states. As the majority of Gastrointestinal Neuroendocrine Tumors express Somatostatin receptors (SSTRs), long-acting somatostatin analogs (SSAs) play an important role in the treatment of patients with Gastrointestinal Neuroendocrine Tumors and may result in symptomatic, biochemical, and objective responses.

Further details related to treatment are provided in the report…

Gastrointestinal Neuroendocrine Tumors Epidemiology

The Gastrointestinal Neuroendocrine Tumors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of NETs, Cases of NETs by Grade, Stage-specific Cases of NETs, Cases of NETs by Site, and Cases of NETs by Functional Status in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total number of incident cases of Gastrointestinal Neuroendocrine Tumors in the US was nearly 15,500 cases in 2024 and is projected to increase during the forecasted period due to improved diagnostic capabilities, and enhanced imaging and endoscopic techniques, which enable earlier and more accurate detection of these tumors.
• In the US, the overall incidence of Gastrointestinal Neuroendocrine Tumors was 4 cases per 100,000 with hindgut tumors being the most common. Hindgut, foregut and midgut Gastrointestinal Neuroendocrine Tumors represented 60%, 30.4%, and 9.6% of cases, respectively.
• Among EU4 and the UK, the highest number of cases for Gastrointestinal Neuroendocrine Tumors was found in the UK which was estimated to be nearly 30% of cases in EU4 and the UK in 2024.
• The establishment of comprehensive cancer registries and better reporting systems are now providing more accurate data on the incidence of Gastrointestinal Neuroendocrine Tumors. This is helping in understanding the true incidence of these tumors.
• The most common Gastrointestinal Neuroendocrine Tumors incidence rate is seen from the stomach (5%), small intestine (12%), rectum (17.5%), and colon (3.5%).

Gastrointestinal Neuroendocrine Tumors Drug Analysis

The drug chapter segment of the Gastrointestinal Neuroendocrine Tumors report encloses a detailed analysis of the marketed and the late, mid, and early stage (Phase III, Phase II, and Phase I/II) pipeline drugs. The marketed drugs segment encloses drugs such as LUTATHERA (lutetium Lu 177 dotatate), AFINITOR (everolimus), SOMATULINE DEPOT (lanreotide), SANDOSTATIN (octreotide), ZANOSAR (streptozocin), and SANDOSTATIN LAR DEPOT. The drug chapter also helps understand the Gastrointestinal Neuroendocrine Tumors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Gastrointestinal Neuroendocrine Tumors Marketed Drugs

LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate (177Lu-DOTATATE; LUTATHERA), belongs to an emerging form of treatment called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumors with molecules carrying radioactive particles that bind to specific receptors expressed by the cancer. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analog DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays a higher uptake of radioactivity in tumors and better residence times. In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated lower whole-body retention, indicating a potentially lower risk for bone marrow toxicity. The presence of a radioligand allows monitoring of treatment response post-therapy and before the next fraction of the dose delivery, which may be clinically beneficial in estimating the intensity of lesion uptakes or deciding the dose for subsequent administrations.

• In May 2025, Advanced Accelerator Applications, a Novartis Company, has taken the decision to withdraw the Type II variation application to extend the indication of LUTATHERA, for the treatment of newly diagnosed, unresectable or metastatic, well-differentiated (Grade (G2) and G3), somatostatin receptor-positive GEP-NETs in adults.
• In April 2024, LUTATHERA was approved for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs.

SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

SOMATULINE DEPOT is a somatostatin analog indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-NETs to improve progression-free survival (PFS). The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting somatostatin analog rescue therapy. The drug is administered subcutaneously. In December 2014, Ipsen Biopharmaceuticals announced that SOMATULINE DEPOT was approved by the US FDA for the treatment of GEP-NETs in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve PFS.

• In September 2017, the FDA approved a supplemental indication for SOMATULINE DEPOT injection 120 mg for the treatment of carcinoid syndrome and in June 2019 the FDA approved a new pre-filled syringe for SOMATULINE DEPOT.
• In May 2024, Cipla announced that it had received the final approval for its Abbreviated New Drug Application (ANDA) for lanreotide injection 120 mg/0.5 mL, 90 mg/0.3 mL, and 60 mg/0.2 mL from the US FDA.

Note: Detailed list will be provided in the final report.

Gastrointestinal Neuroendocrine Tumors Emerging Drugs

ITM-11 (n.c.a. 177Lu-edotreotide): ITM Solucin GmbH

ITM-11 (177Lu-edotreotide) is known as an innovative targeted radionuclide therapy agent and it consists of two molecular components – firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope. ITM-11 received an orphan designation as a treatment for GEP-NETs based on the data from a Phase II clinical study, which demonstrated a significant benefit. Furthermore, a uniquely low uptake by normal organs and a high tumor-to-kidney ratio were shown.

ITM-11 is currently being evaluated in ITM’s two Pivotal Phase III clinical trials, COMPETE and COMPOSE. While COMPETE (NCT03049189) is evaluating ITM-11 for the treatment of patients with Grade 1 and Grade 2 GEP-NETs, the radiopharmaceutical candidate is also being investigated in COMPOSE (NCT04919226), for patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs.

• In June 2025, ITM Isotope Technologies Munich SE announced that they have presented data from their completed Phase III COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Louisiana.
• In March 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today presented positive topline data from its Phase III COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the 22nd Annual European Neuroendocrine Tumor Society (ENETS) 2025.

CAM2029: Camurus

CAM2029 is a long-acting octreotide subcutaneous depot under development for the treatment of three rare diseases: acromegaly, GEP-NET, and polycystic liver disease (PLD). The randomized, active-controlled Pivotal Phase III SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with GEP-NETs progressed. The randomized part of the study is expected to be completed in the early part of 2026. Aside from the clinical study, preparations are also underway for the commercialization of CAM2029 in GEP-NET.

According to the Q1 2024 financial report, NDA/MAA submission based on the SORENTO trial for GEP-NETs is estimated in the second half of 2025. According to the annual 2024 interim report, primary study results of SORENTO trial for CAM2029 are anticipated in late 2025 or early 2026.

Note: Detailed list will be provided in the final report.

Gastrointestinal Neuroendocrine Tumors Drug Class Analysis

The drug classes for both marketed and emerging therapies in Gastrointestinal Neuroendocrine Tumors include somatostatin analogs (LUTATHERA, SOMATULINE DEPOT, and SANDOSTATIN LAR DEPOT); SSTR agonists (ITM-11 [n.c.a. ¹77Lu-edotreotide] and CAM2029); as well as SSTR2 inhibitors (RYZ101), among others.

SSTR agonists

SSTR agonists are internalized following high-affinity binding to their receptors and have traditionally been employed for in vivo targeting of SSTR receptors. This process is regarded as a crucial step in the in vivo targeting of receptors with SSTR agonists. The evolving PET/CT technology and the optimization of radiopharmaceutical chelation for effective somatostatin analog development opened the door to [68Ga] Ga-DOTA0-Tyr3-octreotate ([68Ga] Ga-DOTATATE) PET/CT. The standardized uptake value (SUV) of 68Ga-DOTA-SSA PET/CT in Gastrointestinal Neuroendocrine Tumors patients is related to the expression of SSTR2 and can serve as a distinct predictor of overall survival.

Somatostatin analogs

Somatostatin analogs (SSAs) are synthetic versions of the hormone somatostatin and play a central role in the management of Gastrointestinal Neuroendocrine Tumors. These agents, including octreotide and lanreotide, exert their effects by binding primarily to somatostatin receptors 2 and 5 (SSTR2 and SSTR5) on tumor cells. They help inhibit the secretion of various bioactive substances such as serotonin and gastrin, making them particularly effective in controlling symptoms associated with functional NETs, like carcinoid syndrome. Beyond symptomatic relief, SSAs also exhibit antiproliferative properties by slowing tumor growth and reducing angiogenesis. In addition to therapeutic use, radiolabeled somatostatin analogs are also integral to diagnostic imaging and peptide receptor radionuclide therapy (PRRT), further expanding their utility in the comprehensive management of NETs.

Note: Detailed insights will be provided in the final report.

Gastrointestinal Neuroendocrine Tumors Market Outlook

The therapeutic landscape for gastrointestinal neuroendocrine tumors (Gastrointestinal Neuroendocrine Tumors) continues to rely heavily on a core set of established treatments aimed at symptom control and disease stabilization rather than curative intent. Somatostatin analogs such as SOMATULINE DEPOT and SANDOSTATIN LAR DEPOT remain frontline therapies for both functional and nonfunctional NETs, helping to suppress hormone secretion and delay tumor progression in well-differentiated cases. Radioligand therapies like LUTATHERA (¹77Lu-DOTATATE) have further expanded treatment options for somatostatin receptor–positive disease, offering a targeted approach with demonstrable improvements in PFS. Newer radiopharmaceuticals, such as ITM-11 (n.c.a. ¹77Lu-edotreotide), are emerging with the potential for improved tumor targeting and safety profiles. Despite these advances, challenges remain—particularly in managing receptor-negative tumors, high-grade neuroendocrine carcinomas, and cases with widespread metastasis or resistance to first-line therapies.

Encouragingly, the treatment paradigm is shifting toward more precise, biologically guided strategies. Investigational agents such as the next-generation somatostatin receptor modulators like CAM2029 and RYZ101 are designed to improve targeting efficiency and patient tolerability. Parallel developments in diagnostic tools, including gene expression assays like the NETest and circulating tumor biomarkers, hold promise for earlier diagnosis and real-time disease monitoring. These innovations reflect a broader movement toward multimodal, mechanism-driven care that integrates targeted radiotherapy, immunomodulation, and precision diagnostics. However, most of these agents remain in early-phase trials, and currently no therapy offers a comprehensive solution for aggressive or poorly differentiated NETs. As the clinical understanding of Gastrointestinal Neuroendocrine Tumors deepens, sustained research and development efforts will be critical to advancing safer, more effective, and more personalized treatments for this complex and often overlooked class of tumors.

Gastrointestinal Neuroendocrine Tumors Recent Breakthroughs and Developments

• In May 2025, Advanced Accelerator Applications, a Novartis Company, has taken the decision to withdraw the Type II variation application to extend the indication of Lutathera, for the treatment of newly diagnosed, unresectable or metastatic, well-differentiated (Grade (G2) and G3), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) in adults.
• In June 2025, ITM Isotope Technologies Munich SE announced that they have presented data from their completed Phase III COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Louisiana.
• In March 2025, ITM Isotope Technologies Munich SE (ITM) presented positive topline data from its Phase III COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the 22nd Annual European Neuroendocrine Tumor Society (ENETS) 2025.
• According to the Camurus’s annual 2024 interim report, primary study results of SORENTO trial for CAM2029 are anticipated in late 2025 or early 2026.

 Gastrointestinal Neuroendocrine Tumors Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034. The landscape of Gastrointestinal Neuroendocrine Tumors treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncology professionals, and the entire healthcare community in their tireless pursuit of advancing cancer care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Further detailed analysis of emerging therapies drug uptake in the report…

Gastrointestinal Neuroendocrine Tumors Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Gastrointestinal Neuroendocrine Tumors emerging therapy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on GI-NET's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.

Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as - Fukuoka Sanno Hospital, Smilow Cancer Hospital Yale Cancer Center, National Institutes of Health in the USA, Keio University Hospital in Japan, University of Iowa Hospitals & Clinics in the US, University of Milan in Italy, Moffitt Cancer Center, MD Anderson Cancer Center Madrid, Universitätsmedizin Berlin in Germany etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Gastrointestinal Neuroendocrine Tumors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT Analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, PFS and ORR one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Globally, Gastrointestinal Neuroendocrine Tumors patient families spend an essential proportion of their household income on Gastrointestinal Neuroendocrine Tumors care. Gastrointestinal Neuroendocrine Tumors patients have to face a huge economic burden alone without any healthcare coverage or proper reimbursement policies.

LUTATHERA

Novartis Patient Support

Novartis Patient Support is a comprehensive program that helps patients start and stay on treatment. It helps patients with:

• Navigating the insurance process: A dedicated Novartis Patient Support team will work with the provider to help navigate insurance coverage for the patient’s medication.
• Getting financial support: If the patient has private insurance, they could be eligible for Co-Pay Plus and pay as little as USD 25 for their LUTATHERA treatment. Limitations apply - Up to USD 15,000 throughout the treatment. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice.
• Answering questions across the treatment journey: Speak to a live Novartis Patient Support agent about what to expect before, during, or after treatment.

SOMATULINE DEPOT Co-pay Assistance Program

Eligible patients may pay as little as USD 0 per prescription.

Key Eligibility Criteria:

• The patient currently has commercial (private) health insurance that covers SOMATULINE DEPOT.
• The patient also has no primary or secondary insurance coverage under any state or federal healthcare program.
• The patient has a residency in the US.
• The patient has a valid prescription for SOMATULINE DEPOT.

Further detailed analysis of emerging therapies drug uptake in the report…

Scope of the Gastrointestinal Neuroendocrine Tumors Market Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Gastrointestinal Neuroendocrine Tumors, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Gastrointestinal Neuroendocrine Tumors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Gastrointestinal Neuroendocrine Tumors market.

Gastrointestinal Neuroendocrine Tumors Market Report Insights

• Patient Population
• Therapeutic Approaches
• Gastrointestinal Neuroendocrine Tumors Pipeline Analysis
• Gastrointestinal Neuroendocrine Tumors Market Size and Trends
• Existing and Future Market Opportunity

Gastrointestinal Neuroendocrine Tumors Market Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Gastrointestinal Neuroendocrine Tumors Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Gastrointestinal Neuroendocrine Tumors Market Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT Analysis and Conjoint Analysis)

FAQs

• What was the Gastrointestinal Neuroendocrine Tumors market size, the market size by therapies, market share (%) distribution in 2024, and what would it look like by 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved therapies?
• What can be the future treatment paradigm of Gastrointestinal Neuroendocrine Tumors?
• What are the disease risks, burdens, and unmet needs of Gastrointestinal Neuroendocrine Tumors? What will be the growth opportunities across the 7MM concerning the patient population with Gastrointestinal Neuroendocrine Tumors?
• Who is the major competitor of LUTATHERA in the market?
• What are the current options for the treatment of Gastrointestinal Neuroendocrine Tumors? What are the current guidelines for treating Gastrointestinal Neuroendocrine Tumors in the US, Europe, and Japan?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Gastrointestinal Neuroendocrine Tumors market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.